A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Shionogi
- Study ID
- NCT07214571
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Respiratory Syncytial Virus Infections
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- S-337395 — DRUGS-337395 will be administered per schedule specified in the arm description.
- Placebo — DRUGPlacebo matched to S-337395 will be administered per schedule specified in the arm description.
Study Details
The main purpose of this study is to investigate the antiviral effect of S-337395 compared with placebo among nonhospitalized adult participants with high-risk factors for progression to severe RSV infection starting intervention within 72 hours of RSV symptom onset.
Key Dates
- Start date
- Dec 11, 2025
- Status verified
- Jun 2026
- Primary completion
- Dec 30, 2026
- Completion
- Dec 30, 2026
Study Design
- Enrollment
- 192 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: S-337395 High DoseParticipants will receive a high dose of S-337395 twice daily (BID) orally for up to 5 days.
- Experimental: S-337395 Low DoseParticipants will receive a low dose of S-337395 BID orally for up to 5 days.
- Placebo Comparator: PlaceboParticipants will receive matching placebo BID orally for 5 days.
Primary Outcome Measure
Change From Baseline in RSV Ribonucleic Acid (RNA) Load by Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) (Nasopharyngeal Swab) at Day 2 [ Time Frame: Baseline, Day 2 ]
Central Contacts
- Shionogi Clinical Trials Administrator Clinical Support Help Line800-849-9707
Locations (33)
Find similar trials in Los Angeles, CA
By research site
Related Studies
- Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in ChildrenPHASE3 · Recruiting · University of Alabama at Birmingham · Birmingham, Alabama
- A Study of BLB-201 RSV Vaccine in Infants and ChildrenPHASE1/PHASE2 · Recruiting · Blue Lake Biotechnology Inc. · La Mesa, California
- A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney TransplantPHASE2 · Recruiting · GlaxoSmithKline · Lexington, Kentucky